Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia by Reichard, Holly A, Schiffer, Hans H, Monenschein, Holger, Atienza, Josephine M, Corbett, Gerard, Skaggs, Alton W, Collia, Deanna R, Ray, William J, Serrats, Jordi, Bliesath, Joshua, Kaushal, Nidhi, Lam, Betty P, Amador-Arjona, Alejandro, Rahbaek, Lisa, McConn, Donavon J, Mulligan, Victoria J, Brice, Nicola, Gaskin, Philip L. R, Cilia, Jackie, Hitchcock, Stephen

Get full text

Lysosomes contribute to anomalous pharmacokinetic behavior of melanocortin-4 receptor agonists by YUPING GONG, ZHIYANG ZHAO, MCCONN, Donavon J, BEAUDET, Beth, TALLMAN, Melanie, SPEAKE, Jason D, IGNAR, Diane M, KRISE, Jeffrey P

Get full text

Dose-Related Reduction in Bupropion Plasma Concentrations by Ritonavir by Park, Joohyun, Vousden, Marika, Brittain, Claire, McConn, Donavon J., Iavarone, Laura, Ascher, John, Sutherland, Suzanne M., Muir, Keith T.

Get full text

Reduced Duodenal Cytochrome P450 3A Protein Expression and Catalytic Activity in Patients With Cirrhosis by McConn, DJ, Lin, YS, Mathisen, TL, Blough, DK, Xu, Y, Hashizume, T, Taylor, SL, Thummel, KE, Shuhart, MC

Get full text

Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)‑5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro‑3H‑1,2,4-triazol-3-one, by Fra... by Sabat, Mark, Dougan, Douglas R, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Get full text

Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-triazol-3-one, by... by Sabat, Mark, Dougan, Douglas R, Knight, Beverly, Lawson, J David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Get full text

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (S)‑5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro‑3H‑1,2,4-triazo... by Sabat, Mark, Dougan, Douglas R, Ermolieff, Jacques, Halkowycz, Petro, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Get full text

Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ( S )-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3 H -1,2,4-tr... by Sabat, Mark, Dougan, Douglas R, Ermolieff, Jacques, Halkowycz, Petro, Knight, Beverly, Lawson, J. David, Scorah, Nicholas, Smith, Christopher R, Taylor, Ewan R, Vu, Phong, Wyrick, Corey, Wang, Haixia, Balakrishna, Deepika, Hixon, Mark, Madakamutil, Loui, McConn, Donavon

Get full text

2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV by Haffner, Curt D., McDougald, Darryl L., Reister, Steven M., Thompson, Brian D., Conlee, Christopher, Fang, Jing, Bass, Jonathan, Lenhard, James M., Croom, Dallas, Secosky-Chang, Melissa B., Tomaszek, Thaddeus, McConn, Donavon, Wells-Knecht, Kevin, Johnson, Paul R.

Get full text